MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

227.04
+2.12
+0.94%
Closed 17:18 03/01 EST
OPEN
225.88
PREV CLOSE
224.92
HIGH
227.93
LOW
225.23
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
276.69
52 WEEK LOW
177.05
MARKET CAP
131.13B
P/E (TTM)
18.44
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The impact of COVID-19 on Biologics (Biosimilar) Market Size 2021 Global Industry Trends, Growth, Share, Size and 2026 Forecast Research Report
Mar 02, 2021 (The Expresswire) -- The report provides revenue of the globalBiologics (Biosimilar) Market for the period 2016 and 2026, considering 2020 as...
The Express Wire · 4h ago
Immunology Market Size 2021 By Industry Expansion Strategies, Development Trends, Modest Analysis, Business Prospect, Regional Growth, End User Analysis and Forecast to 2025 Says Industry Research Biz
Mar 02, 2021 (The Expresswire) -- Global “Immunology Market” report is extensive significant analyses of the Immunology industry and provides data for making...
The Express Wire · 4h ago
Cancer Biological Theraphy Market Share, Growth, Size 2021: Global Sales Revenue, Emerging Technologies, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2023
Mar 02, 2021 (The Expresswire) -- Global Cancer Biological Theraphy Market Research Report presents competitive environment such as key competitors, key...
The Express Wire · 5h ago
Europe Cancer Therapeutics Market Size ,Share 2021 Global Growth, Trends, Industry Analysis, Statistics,Development Status ,Key Players and Forecast to 2024
Mar 02, 2021 (The Expresswire) -- Global Europe Cancer Therapeutics Market research report provides a Point-by-Point In-Depth analysis of global market size,...
The Express Wire · 5h ago
Europe Cancer Therapeutics Market Share,Size 2021 – Global Trends, Market Demand, Industry Analysis, Growth, Opportunities and Forecast 2024
The Express Wire · 5h ago
Vasomotor Symptoms of Menopause Treatment Market 2021 Top Manufacturers Strategy, Industry Share, Growth Factors, Development Trends and 2027 Forecast| Industry Research Biz
The Express Wire · 6h ago
Immunology Market 2021 : Market Size, Segmentation Analysis, Industry Status and Revenue Forecast Recorded During Forecast to 2026 with Top Countries Data
Mar 01, 2021 (The Expresswire) -- According to 360 Research Reports, the “Immunology Market" 2021 by Types (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque...
The Express Wire · 9h ago
Amgen Inc. stock rises Monday, still underperforms market
Shares of Amgen Inc. inched 0.94% higher to $227.04 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...
marketwatch.com · 13h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 30 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMGN stock price target is 255.09 with a high estimate of 301.00 and a low estimate of 185.00.
EPS
Institutional Holdings
Institutions: 2.85K
Institutional Holdings: 464.09M
% Owned: 80.35%
Shares Outstanding: 577.57M
TypeInstitutionsShares
Increased
865
12.12M
New
338
1.35M
Decreased
750
20.68M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.05%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President/Chief Compliance Officer
Cynthia Patton
Senior Vice President/General Counsel/Secretary
Jonathan Graham
Senior Vice President/Director of Human Resources
Lori Johnston
Senior Vice President
David Piacquad
Chief Accounting Officer/Vice President - Finance
Linda Louie
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Fred Hassan
Independent Director
Charles Holley
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
R. Sanders Williams
Independent Director
Robert Williams
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/16/2020
Dividend USD 1.76
02/11/2021
10/21/2020
Dividend USD 1.6
11/13/2020
07/23/2020
Dividend USD 1.6
08/14/2020
03/04/2020
Dividend USD 1.6
05/15/2020
12/11/2019
Dividend USD 1.6
02/13/2020
10/22/2019
Dividend USD 1.45
11/14/2019
08/02/2019
Dividend USD 1.45
08/14/2019
03/07/2019
Dividend USD 1.45
05/16/2019
12/07/2018
Dividend USD 1.45
02/14/2019
10/23/2018
Dividend USD 1.32
11/15/2018
07/31/2018
Dividend USD 1.32
08/16/2018
03/07/2018
Dividend USD 1.32
05/16/2018
12/12/2017
Dividend USD 1.32
02/14/2018
10/24/2017
Dividend USD 1.15
11/16/2017
07/28/2017
Dividend USD 1.15
08/15/2017
03/07/2017
Dividend USD 1.15
05/15/2017
12/20/2016
Dividend USD 1.15
02/13/2017
10/14/2016
Dividend USD 1
11/14/2016
07/22/2016
Dividend USD 1
08/15/2016
03/02/2016
Dividend USD 1
05/13/2016
12/15/2015
Dividend USD 1
02/11/2016
10/14/2015
Dividend USD 0.79
11/12/2015
07/28/2015
Dividend USD 0.79
08/13/2015
03/04/2015
Dividend USD 0.79
05/12/2015
12/17/2014
Dividend USD 0.79
02/10/2015
10/17/2014
Dividend USD 0.61
11/10/2014
07/25/2014
Dividend USD 0.61
08/12/2014
03/05/2014
Dividend USD 0.61
05/13/2014
12/13/2013
Dividend USD 0.61
02/11/2014
10/16/2013
Dividend USD 0.47
11/12/2013
07/26/2013
Dividend USD 0.47
08/14/2013
03/06/2013
Dividend USD 0.47
05/14/2013
12/13/2012
Dividend USD 0.47
02/11/2013
10/10/2012
Dividend USD 0.36
11/13/2012
07/19/2012
Dividend USD 0.36
08/14/2012
03/15/2012
Dividend USD 0.36
05/14/2012
12/15/2011
Dividend USD 0.36
02/13/2012
10/13/2011
Dividend USD 0.28
11/15/2011
07/28/2011
Dividend USD 0.28
08/16/2011
  • All
  • Financials
  • Insiders
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.